SCHEMBL1704531

SCHEMBL1704531

NC(=O)CCCC1=CC(=O)NC1=O

nearest known ligand 0.34

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CAPN1 P07384 1/20 0.33
MPO P05164 2/20 0.32
SLC6A4 P31645 1/20 0.32
ATM Q13315 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL548121 0.82 STAT3 (0.35)
SCHEMBL5703319 0.82 STAT3 (0.31)
SCHEMBL10428620 0.80 STAT3 (0.39)
SCHEMBL549066 0.80 STAT3 (0.39)
SCHEMBL548131 0.80 STAT3 (0.39)
SCHEMBL6910095 0.80 STAT3 (0.39)
SCHEMBL586641 0.80 STAT3 (0.39)
SCHEMBL549041 0.80 STAT3 (0.39)
SCHEMBL10428730 0.80 STAT3 (0.39)
SCHEMBL4821000 0.79 DAO (0.32)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008157824-A2 THROMBOPOIETIN PEPTIDE CONJUGATES CONJUCHEM BIOTECHNOLOGIES INC. (CA) 2008-12-24 WO claimed
EP-4313009-A1 MAYTANSINE-ANTIBODY CONJUGATES AND METHODS OF USING SAME Angiex, Inc. (US) 2024-02-07 EP disclosed
WO-2023239803-A1 ANTI-TM4SF1 ANTIBODY-DRUG CONJUGATES COMPRISING CLEAVABLE LINKERS AND METHODS OF USING SAME ANGIEX, INC. (US) 2023-12-14 WO disclosed
EP-4204013-A1 ANTIMITOTIC TETRAPEPTIDE-ANTIBODY CONJUGATES AND METHODS OF USING SAME Angiex, Inc. (US) 2023-07-05 EP disclosed
EP-4188449-A2 ANTI-TM4SF1 ANTIBODY-DRUG CONJUGATES COMPRISING CLEAVABLE LINKERS AND METHODS OF USING SAME Angiex, Inc. (US) 2023-06-07 EP disclosed
WO-2022026915-A9 ANTI-TM4SF1 ANTIBODY-DRUG CONJUGATES COMPRISING CLEAVABLE LINKERS AND METHODS OF USING SAME ANGIEX, INC. (US) 2022-04-28 WO disclosed
WO-2022046941-A1 ANTIMITOTIC TETRAPEPTIDE-ANTIBODY CONJUGATES AND METHODS OF USING SAME ANGIEX, INC. (US) 2022-03-03 WO disclosed
WO-2022026915-A2 ANTI-TM4SF1 ANTIBODY-DRUG CONJUGATES COMPRISING CLEAVABLE LINKERS AND METHODS OF USING SAME ANGIEX, INC. (US) 2022-02-03 WO disclosed
WO-2021222783-A1 ANTI-TM4SF1 ANTIBODY DRUG CONJUGATES AND METHODS OF USING SAME ANGIEX, INC. (US) 2021-11-04 WO disclosed
EP-3625245-A1 PEPTIDE COMPOUNDS, CONJUGATE COMPOUNDS AND USES THEREOF FOR TREATING INFLAMMATORY DISEASES Transfert Plus, S.E.C. (CA) 2020-03-25 EP disclosed
WO-2010142035-A1 FUSION PROTEINS FOR DELIVERY OF GDNF AND BDNF TO THE CENTRAL NERVOUS SYSTEM ANGIOCHEM INC. (CA) 2010-12-16 WO disclosed
EP-2231191-A2 FORMULATION OF INSULINOTROPIC PEPTIDE CONJUGATES ConjuChem Biotechnologies Inc. (CA) 2010-09-29 EP disclosed
WO-2010069074-A1 MEMBRANE TYPE-1 MATRIX METALLOPROTEIN INHIBITORS AND USES THEREOF UNIVERSITE DU QUEBEC A MONTREAL (CA) 2010-06-24 WO disclosed
WO-2010063124-A1 PEPTIDE THERAPEUTIC CONJUGATES AND USES THEREOF ANGIOCHEM INC. (CA) 2010-06-10 WO disclosed
WO-2010063123-A1 LEPTIN AND LEPTIN ANALOG CONJUGATES AND USES THEREOF ANGIOCHEM INC. (CA) 2010-06-10 WO disclosed
WO-2010063122-A1 CONJUGATES OF NEUROTENSIN OR NEUROTENSIN ANALOGS AND USES THEREOF ANGIOCHEM INC. (CA) 2010-06-10 WO disclosed
WO-2010043047-A1 CONJUGATES OF GLP-1 AGONISTS AND USES THEREOF ANGIOCHEM INC. (CA) 2010-04-22 WO disclosed
EP-2114437-A2 MODIFIED CORTICOTROPIN RELEASING FACTOR PEPTIDES AND USES THEREOF ConjuChem Biotechnologies Inc. (CA) 2009-11-11 EP disclosed
WO-2009075859-A2 FORMULATION OF INSULINOTROPIC PEPTIDE CONJUGATES CONJUCHEM BIOTECHNOLOGIES INC. (CA) 2009-06-18 WO disclosed
WO-2008047241-A2 MODIFIED CORTICOTROPIN RELEASING FACTOR PEPTIDES AND USES THEREOF CONJUCHEM BIOTECHNOLOGIES INC. (US) 2008-04-24 WO disclosed